Vitruvias Therapeutics Inc. has announced a voluntary, nationwide recall of one lot of Thyroid Tablets, USP 30 mg, affecting Lot Number 504950. Routine testing revealed that the medication has the potential to be superpotent, meaning it contains higher levels of active ingredients than intended.

The affected batch includes 3,655 units distributed nationwide to direct accounts between January 31, 2025, and September 30, 2025. The recalled tablets feature National Drug Code (NDC) 69680-166-00 and an expiration date of September 30, 2026.

Consuming superpotent thyroid medication can lead to hyperthyroidism, resulting in symptoms such as rapid heart rate, weight loss, chest pain, nervousness, and muscle weakness. Vulnerable populations, including the elderly, pregnant women, and infants, face heightened risks of severe health complications, ranging from cardiac stress to developmental impacts and premature delivery. To date, Vitruvias Therapeutics has not received any reports of adverse events linked to the recall.

The company is actively contacting wholesalers via email and phone to halt distribution and arrange for the destruction of the affected lot. Patients currently taking the recalled 30 mg tablets are advised not to stop taking their medication without first consulting their healthcare provider for guidance or a replacement prescription.

Consumers with questions or concerns regarding the recall can reach Vitruvias Therapeutics by phone at (256) 239-9373 or via email at [email protected] on weekdays between 9 a.m. and 5 p.m. CT. Adverse reactions or quality issues can also be reported directly to the U.S. Food and Drug Administration’s MedWatch program.